Streptococcal superantigens: Categorization and clinical associations

Trends in Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 48-62

  Commons, Robert J ^a,b   Smeesters, Pierre R ^b,c   Proft, Thomas ^d   Fraser, John D ^d   Robins Browne, Roy ^a,b   Curtis, Nigel ^a,b,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Invasive disease; Nomenclature; Streptococcus; Toxic shock; Toxin

Indexed keywords

SMEZ PROTEIN; SPEA PROTEIN; SPEC PROTEIN; SPEG PROTEIN; SPEJ PROTEIN; SPEK PROTEIN; SSA PROTEIN; STREPTOCOCCAL SUPERANTIGEN; STREPTOCOCCUS ANTIGEN; SUPERANTIGEN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ALLELE; BACTERIAL STRAIN; BACTERIUM ISOLATE; GENETIC VARIABILITY; GROUP A STREPTOCOCCAL INFECTION; HISTOPATHOLOGY; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOPLASMA ARTHRITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRACTICE GUIDELINE; PREVALENCE; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SCARLET FEVER; SEROLOGY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; UNINDEXED SEQUENCE; YERSINIA PSEUDOTUBERCULOSIS;

STREPTOCOCCUS; STREPTOCOCCUS SP. 'GROUP A';

INVASIVE DISEASE; NOMENCLATURE; STREPTOCOCCUS; TOXIC SHOCK; TOXIN;

HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PSORIASIS; RHEUMATIC FEVER; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; SUPERANTIGENS;

EID: 84891371926     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.10.004     Document Type: Review

References (135)

1. Carapetis J.R., et al. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 2005, 5:685-694.
2. Parks T., et al. Streptococcal skin infection and rheumatic heart disease. Curr. Opin. Infect. Dis. 2012, 25:145-153.
3. Lappin E., Ferguson A.J. Gram-positive toxic shock syndromes. Lancet Infect. Dis. 2009, 9:281-290.
4. Bramhachari P.V., et al. Disease burden due to Streptococcus dysgalactiae subsp. equisimilis (group G and C streptococcus) is higher than that due to Streptococcus pyogenes among Mumbai school children. J. Med. Microbiol. 2010, 59:220-223.
5. Yamaoka S., et al. Neonatal streptococcal toxic shock syndrome caused by Streptococcus dysgalactiae subsp. equisimilis. Pediatr. Infect. Dis. J. 2010, 29:979-981.
6. Igwe E.I., et al. Identification of superantigen genes speM, ssa, and smeZ in invasive strains of β-hemolytic group C and G streptococci recovered from humans. FEMS Microbiol. Lett. 2003, 229:259-264.
7. Igwe E.I., et al. Corrigendum: Identification of superantigen genes speM, ssa, and smeZ in invasive strains of beta-hemolytic group C and G streptococci recovered from humans. FEMS Microbiol. Lett. 2010, 310:193.
8. Smeesters P.R., et al. Group A Streptococcus virulence and host factors in two toddlers with rheumatic fever following toxic shock syndrome. Int. J. Infect. Dis. 2010, 14:e403-e409.
9. Johansson L., et al. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin. Infect. Dis. 2010, 51:58-65.
10. Nooh M.M., et al. Individual genetic variations directly effect polarization of cytokine responses to superantigens associated with streptococcal sepsis: implications for customized patient care. J. Immunol. 2011, 186:3156-3163.
11. Smeesters P.R., et al. The streptococcal M protein: a highly versatile molecule. Trends Microbiol. 2010, 18:275-282.
12. Pahlman L.I., et al. Soluble M1 protein of Streptococcus pyogenes triggers potent T cell activation. Cell. Microbiol. 2008, 10:404-414.
13. Facklam R.F., et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin. Infect. Dis. 2002, 34:28-38.
14. McMillan D.J., et al. Recombination drives genetic diversification of Streptococcus dysgalactiae subspecies equisimilis in a region of streptococcal endemicity. PLoS ONE 2011, 6:e21346.
15. Cole J.N., et al. Molecular insight into invasive group A streptococcal disease. Nat. Rev. Microbiol. 2011, 9:724-736.
16. Fraser J.D., Proft T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 2008, 225:226-243.
17. Cole B.C., Atkin C.L. The mycoplasma arthritidis T-cell mitogen, MAM: a model superantigen. Immunol. Today 1991, 12:271-276.
18. + regulatory T cells through stimulation with staphylococcal and streptococcal superantigens. Immunology 2012, 135:158-167.
19. Proft T., Fraser J.D. Streptococcal superantigens. Chem. Immunol. Allergy 2007, 93:1-23.
20. Curtis N. Invasive group A streptococcal infection. Curr. Opin. Infect. Dis. 1996, 9:191-202.
21. Arad G., et al. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. 2000, 6:414-421.
22. Arad G., et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol. 2011, 9:e1001149.
23. Braun M.A., et al. Stimulation of human T cells by streptococcal "superantigen" erythrogenic toxins (scarlet fever toxins). J. Immunol. 1993, 150:2457-2466.
24. Gerlach D., et al. Basic streptococcal superantigens (SPEX/SMEZ or SPEC) are responsible for the mitogenic activity of the so-called mitogenic factor (MF). FEMS Immunol. Med. Microbiol. 2001, 30:209-216.
25. Mollick J.A., et al. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J. Clin. Invest. 1993, 92:710-719.
26. Smoot L.M., et al. Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. Infect. Immun. 2002, 70:7095-7104.
27. Ferretti J.J., et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4658-4663.
28. Beres S.B., et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10078-10083.
29. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32:1792-1797.
30. Proft T., et al. The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J. Exp. Med. 2000, 191:1765-1776.
31. Turner C.E., et al. Superantigenic activity of emm3 Streptococcus pyogenes is abrogated by a conserved, naturally occurring smeZ mutation. PLoS ONE 2012, 7:e46376.
32. Friaes A., et al. Superantigen gene complement of Streptococcus pyogenes - relationship with other typing methods and short-term stability. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32:115-125.
33. McMillan D.J., et al. Variations in the distribution of genes encoding virulence and extracellular proteins in group A streptococcus are largely restricted to 11 genomic loci. Microbes Infect. 2007, 9:259-270.
34. Paillot R., et al. Identification of three novel superantigen-encoding genes in Streptococcus equi subsp. zooepidemicus, szeF, szeN, and szeP. Infect. Immun. 2010, 78:4817-4827.
35. Holden M.T., et al. Genomic evidence for the evolution of Streptococcus equi: host restriction, increased virulence, and genetic exchange with human pathogens. PLoS Pathog. 2009, 5:e1000346.
36. Okumura K., et al. Evolutionary paths of streptococcal and staphylococcal superantigens. BMC Genomics 2012, 13:404.
37. Vlaminckx B.J., et al. Site-specific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J. Clin. Microbiol. 2003, 41:4941-4949.
38. Talkington D.F., et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect. Immun. 1993, 61:3369-3374.
39. Belani K., et al. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr. Infect. Dis. J. 1991, 10:351-354.
40. Musser J.M., et al. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2668-2672.
41. Cleary P.P., et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992, 339:518-521.
42. Carapetis J., et al. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin. Infect. Dis. 1995, 21:1220-1227.
43. Jing H.B., et al. Epidemiological analysis of group A streptococci recovered from patients in China. J. Med. Microbiol. 2006, 55:1101-1107.
44. Eriksson B.K., et al. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J. Infect. Dis. 1999, 180:410-418.
45. Chatellier S., et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 2000, 68:3523-3534.
46. Musser J.M., et al. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin). J. Infect. Dis. 1993, 167:337-346.
47. Ikebe T., et al. Dissemination of the phage-associated novel superantigen gene speL in recent invasive and noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect. Immun. 2002, 70:3227-3233.
48. Mylvaganam H., et al. Distribution and sequence variations of selected virulence genes among group A streptococcal isolates from western Norway. APMIS 2000, 108:771-778.
49. Hsueh P.R., et al. Invasive group A streptococcal disease in Taiwan is not associated with the presence of streptococcal pyrogenic exotoxin genes. Clin. Infect. Dis. 1998, 26:584-589.
50. Descheemaeker P., et al. Molecular characterisation of group A streptococci from invasive and non-invasive disease episodes in Belgium during 1993-1994. J. Med. Microbiol. 2000, 49:467-471.
51. Proft T. Superantigens and streptococcal toxic shock syndrome. Emerg. Infect. Dis. 2003, 9:1211-1218.
52. Rivera A., et al. Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. J. Med. Microbiol. 2006, 55:1115-1123.
53. Reda K.B., et al. Molecular characterization and phylogenetic distribution of the streptococcal superantigen gene (ssa) from Streptococcus pyogenes. Infect. Immun. 1994, 62:1867-1874.
54. Murakami J., et al. Distribution of emm genotypes and superantigen genes of Streptococcus pyogenes isolated in Japan, 1994-1999. Epidemiol. Infect. 2002, 128:397-404.
55. Friaes A., et al. Group A streptococci clones associated with invasive infections and pharyngitis in Portugal present differences in emm types, superantigen gene content and antimicrobial resistance. BMC Microbiol. 2012, 12:280.
56. Lintges M., et al. Superantigen genes are more important than the emm type for the invasiveness of group A streptococcus infection. J. Infect. Dis. 2010, 202:20-28.
57. Haukness H.A., et al. The heterogeneity of endemic community pediatric group A streptococcal pharyngeal isolates and their relationship to invasive isolates. J. Infect. Dis. 2002, 185:915-920.
58. DelVecchio A., et al. NAD-glycohydrolase production and speA and speC distribution in group A streptococcus (GAS) isolates do not correlate with severe GAS diseases in the Australian population. J. Clin. Microbiol. 2002, 40:2642-2644.
59. Proft T., et al. Two novel superantigens found in both group A and group C streptococcus. Infect. Immun. 2003, 71:1361-1369.
60. Rogers S., et al. Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections. J. Infect. Dis. 2007, 195:1625-1633.
61. Hashikawa S., et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J. Clin. Microbiol. 2004, 42:186-192.
62. Davies M.R., et al. Virulence profiling of Streptococcus dysgalactiae subspecies equisimilis isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases. Clin. Infect. Dis. 2007, 44:1442-1454.
63. Brandt C.M., et al. Lack of mitogenic activity of speG- and speG(dys)-positive Streptococcus dysgalactiae subspecies equisimilis isolates from patients with invasive infections. Int. J. Med. Microbiol. 2005, 295:539-546.
64. Zhao J., et al. Cloning, expression, and characterization of the superantigen streptococcal pyrogenic exotoxin G from Streptococcus dysgalactiae. Infect. Immun. 2007, 75:1721-1729.
65. Curtis N., et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1994, 343:299.
66. Abe J., et al. Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4066-4070.
67. Curtis N., et al. Evidence for a superantigen mediated process in Kawasaki disease. Arch. Dis. Child. 1995, 72:308-311.
68. Yoshioka T., et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999, 96:465-472.
69. Yoshioka T., et al. Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. Pediatr. Res. 2003, 53:403-410.
70. Matsubara K., et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin. Exp. Immunol. 2006, 143:427-434.
71. Morita A., et al. Serologic evidence that streptococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol. Immunol. 1997, 41:895-900.
72. Nomura Y., et al. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J. Infect. Dis. 2002, 185:1677-1680.
73. Gupta-Malhotra M., et al. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. Exp. Mol. Pathol. 2004, 76:117-121.
74. Lee H.H., et al. Immunoglobulin V(H) chain gene analysis of peripheral blood IgM-producing B cells in patients with Kawasaki disease. Yonsei Med. J. 2009, 50:493-504.
75. Lewis H.M., et al. Restricted T-cell receptor Vβ gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br. J. Dermatol. 1993, 129:514-520.
76. Leung D.Y., et al. A potential role for superantigens in the pathogenesis of psoriasis. J. Invest. Dermatol. 1993, 100:225-228.
77. Leung D.Y., et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 1995, 96:2106-2112.
78. Horiuchi N., et al. Peripheral blood lymphocytes from psoriatic patients are hyporesponsive to β-streptococcal superantigens. Br. J. Dermatol. 1998, 138:229-235.
79. Tokura Y., et al. Hyporesponsiveness of peripheral blood lymphocytes to streptococcal superantigens in patients with guttate psoriasis: evidence for systemic stimulation of T cells with superantigens released from focally infecting Streptococcus pyogenes. Arch. Dermatol. Res. 1999, 291:382-389.
80. El Ferezli J., et al. Streptococcus sp. and Staphylococcus aureus isolates from patients with psoriasis possess genes that code for toxins (superantigens): clinical and therapeutic implications. Immunopharmacol. Immunotoxicol. 2008, 30:195-205.
81. Thomssen H., et al. There is no disease-specific role for streptococci-responsive synovial T lymphocytes in the pathogenesis of psoriatic arthritis. Med. Microbiol. Immunol. 2000, 188:203-207.
82. Valdimarsson H., et al. Psoriasis - as an autoimmune disease caused by molecular mimicry. Trends Immunol. 2009, 30:494-501.
83. Travers J.B., et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J. Clin. Invest. 1999, 104:1181-1189.
84. Dick G.F., Dick G.H. The etiology of scarlet fever. J. Am. Med. Assoc. 1924, 82:301-302.
85. Abe J., et al. Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J. Immunol. 1991, 146:3747-3750.
86. Tse H., et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J. Infect. Dis. 2012, 206:341-351.
87. Tripathi A., et al. Immunoglobulin E to staphylococcal and streptococcal toxins in patients with chronic sinusitis/nasal polyposis. Laryngoscope 2004, 114:1822-1826.
88. Shiobara N., et al. Bacterial superantigens and T cell receptor β-chain-bearing T cells in the immunopathogenesis of ulcerative colitis. Clin. Exp. Immunol. 2007, 150:13-21.
89. Dar S.A., et al. Possible role of superantigens in inducing autoimmunity in pemphigus patients. J. Dermatol. 2011, 38:980-987.
90. Fontana A., et al. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss?. Brain 2010, 133:1300-1311.
91. Kearse M., et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012, 28:1647-1649.
92. Petersen T.N., et al. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat. Methods 2011, 8:785-786.
93. Green N.M., et al. Genome sequence of a serotype M28 strain of group A streptococcus: potential new insights into puerperal sepsis and bacterial disease specificity. J. Infect. Dis. 2005, 192:760-770.
94. Nakagawa I., et al. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res. 2003, 13:1042-1055.
95. Smoot J.C., et al. Genome sequence and comparative microarray analysis of serotype M18 group A streptococcus strains associated with acute rheumatic fever outbreaks. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:4668-4673.
96. Proft T., Fraser J.D. Bacterial superantigens. Clin. Exp. Immunol. 2003, 133:299-306.
97. Alouf J.E. Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). Pharmacol. Ther. 1980, 11:661-717.
98. Sachse S., et al. Superantigen-like gene(s) in human pathogenic Streptococcus dysgalactiae, subsp equisimilis: genomic localisation of the gene encoding streptococcal pyrogenic exotoxin G (speG(dys)). FEMS Immunol. Med. Microbiol. 2002, 34:159-167.
99. Alber J., et al. Multiplex polymerase chain reaction for identification and differentiation of Streptococcus equi subsp. zooepidemicus and Streptococcus equi subsp. equi. J. Vet. Med. B: Infect. Dis. Vet. Public Health 2004, 51:455-458.
100. Artiushin S.C., et al. Characterization and immunogenicity of pyrogenic mitogens SePE-H and SePE-I of Streptococcus equi. Microb. Pathog. 2002, 32:71-85.
101. Alber J., et al. Dissemination of the superantigen encoding genes seeL, seeM, szeL and szeM in Streptococcus equi subsp. equi and Streptococcus equi subsp. zooepidemicus. Vet. Microbiol. 2005, 109:135-141.
102. Papageorgiou A.C., et al. Expression, purification and crystallization of Streptococcus dysgalactiae-derived mitogen. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 2006, 62:242-244.
103. Miyoshi-Akiyama T., et al. Streptococcus dysgalactiae-derived mitogen (SDM), a novel bacterial superantigen: characterization of its biological activity and predicted tertiary structure. Mol. Microbiol. 2003, 47:1589-1599.
104. Gerlach D., et al. Purification and biochemical characterization of a basic superantigen (SPEX/SMEZ3) from Streptococcus pyogenes. FEMS Microbiol. Lett. 2000, 188:153-163.
105. Tyler S.D., et al. Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J. Clin. Microbiol. 1992, 30:3127-3131.
106. Azuma K., et al. Detection of circulating superantigens in an intensive care unit population. Int. J. Infect. Dis. 2004, 8:292-298.
107. Ekelund K., et al. Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. J. Clin. Microbiol. 2005, 43:3101-3109.
108. McMillan D.J., et al. Genes for the majority of group A streptococcal virulence factors and extracellular surface proteins do not confer an increased propensity to cause invasive disease. Clin. Infect. Dis. 2006, 43:884-891.
109. Kittang B.R., et al. Invasive group A, C and G streptococcal disease in western Norway: virulence gene profiles, clinical features and outcomes. Clin. Microbiol. Infect. 2011, 17:358-364.
110. Sriskandan S., et al. Detection of circulating bacterial superantigen and lymphotoxin-α in patients with streptococcal toxic-shock syndrome. Lancet 1996, 348:1315-1316.
111. Basma H., et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. 1999, 67:1871-1877.
112. Michie C., et al. Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin. Exp. Immunol. 1994, 98:140-144.
113. Watanabe-Ohnishi R., et al. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J. Infect. Dis. 1995, 171:74-84.
114. Thomas D., et al. In vivo and in vitro detection of a superantigenic toxin Vβ signature in two forms of streptococcal toxic shock syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:671-676.
115. Nandi S., et al. Association of pyrogenic exotoxin genes with pharyngitis and rheumatic fever/rheumatic heart disease among Indian isolates of Streptococcus pyogenes. Lett. Appl. Microbiol. 2002, 35:237-241.
116. Abdel-Rehim M., et al. Serum antibodies to group A streptococcal extracellular and cell-associated antigens in Egyptians with post-streptococcal diseases. FEMS Immunol. Med. Microbiol. 2001, 31:21-27.
117. Yang L.P., et al. Variations in the protective immune response against streptococcal superantigens in populations of different ethnicity. Med. Microbiol. Immunol. 2006, 195:37-43.
118. El Demellawy M.A., Farrag A.M. Role of humoral immune response to group A streptococcal pyrogenic exotoxins in rheumatic fever. Egypt. J. Immunol. 2004, 11:157-164.
119. + T cells in peripheral blood from rheumatic heart disease patients. J. Autoimmun. 2003, 20:183-190.
120. Guilherme L., et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int. Immunol. 2000, 12:1063-1074.
121. Figueroa F., et al. Restriction in the usage of variable β regions in T-cells infiltrating valvular tissue from rheumatic heart disease patients. J. Autoimmun. 2002, 19:233-240.
122. Abbott W.G., et al. Repertoire of transcribed peripheral blood T-cell receptor β chain variable-region genes in acute rheumatic fever. Infect. Immun. 1996, 64:2842-2845.
123. Watanabe-Ohnishi R., et al. Characterization of unique human TCR Vβ specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein. J. Immunol. 1994, 152:2066-2073.
124. Tomai M.A., et al. T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein. J. Exp. Med. 1991, 174:285-288.
125. Bhatnagar A., et al. Superantigen-induced T cell responses in acute rheumatic fever and chronic rheumatic heart disease patients. Clin. Exp. Immunol. 1999, 116:100-106.
126. Suenaga T., et al. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J. Pediatr. 2009, 155:266-270.
127. Leung D.Y., et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J. Pediatr. 2002, 140:742-746.
128. Nomura Y., et al. Possible relationship between streptococcal pyrogenic exotoxin A and Kawasaki syndrome in patients older than six months of age. Pediatr. Infect. Dis. J. 2003, 22:794-798.
129. Brogan R.J., et al. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatr. Rheumatol. Online J. 2009, 7:3.
130. Nagata S., et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. Immunology 2009, 128:511-520.
131. + T cells in the small intestinal mucosa in Kawasaki disease. Pediatr. Res. 1996, 39:264-266.
132. Masuda K., et al. Transient low T cell response to streptococcal pyrogenic exotoxin-C in patients with Kawasaki disease. Pediatr. Res. 1998, 44:27-31.
133. Davison S.C., et al. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br. J. Dermatol. 2001, 145:245-251.
134. Aiba S., et al. Decreased IL-10 production by psoriatic peripheral blood mononuclear cells stimulated with streptococcal superantigen. Exp. Dermatol. 2002, 11:337-343.
135. Kotb M., et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. 2002, 8:1398-1404.